Eli Lilly and Company
BTK INHIBITOR COMPOUNDS
Last updated:
Abstract:
The invention provides BTK Inhibitor compounds, pharmaceutically acceptable salts, pharmaceutical compositions thereof, and methods of using these compounds, salts, or compositions to treat autoimmune diseases such as Rheumatoid Arthritis.
Status:
Application
Type:
Utility
Filling date:
30 Oct 2018
Issue date:
17 Sep 2020